JP2020536092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536092A5 JP2020536092A5 JP2020519066A JP2020519066A JP2020536092A5 JP 2020536092 A5 JP2020536092 A5 JP 2020536092A5 JP 2020519066 A JP2020519066 A JP 2020519066A JP 2020519066 A JP2020519066 A JP 2020519066A JP 2020536092 A5 JP2020536092 A5 JP 2020536092A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- administered
- meropenem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 21
- 229960002260 meropenem Drugs 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 241000194033 Enterococcus Species 0.000 claims description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000002071 myeloproliferative effect Effects 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 241000589562 Brucella Species 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 241000589242 Legionella pneumophila Species 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 229940115932 legionella pneumophila Drugs 0.000 claims description 4
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 3
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 3
- 206010008631 Cholera Diseases 0.000 claims description 3
- 241000589602 Francisella tularensis Species 0.000 claims description 3
- 206010018691 Granuloma Diseases 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 3
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 229940118764 francisella tularensis Drugs 0.000 claims description 3
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 3
- 229940013390 mycoplasma pneumoniae Drugs 0.000 claims description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 3
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000606660 Bartonella Species 0.000 claims description 2
- 241000589876 Campylobacter Species 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 241000588914 Enterobacter Species 0.000 claims description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 238000002651 drug therapy Methods 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims description 2
- 208000004235 neutropenia Diseases 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 238000010911 splenectomy Methods 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 241000606685 Bartonella bacilliformis Species 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 241000589874 Campylobacter fetus Species 0.000 claims 1
- 241000588697 Enterobacter cloacae Species 0.000 claims 1
- 241000194031 Enterococcus faecium Species 0.000 claims 1
- 241001534216 Klebsiella granulomatis Species 0.000 claims 1
- 241000589248 Legionella Species 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- 241000607720 Serratia Species 0.000 claims 1
- 241000607626 Vibrio cholerae Species 0.000 claims 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 claims 1
- 229940092528 bartonella bacilliformis Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940118696 vibrio cholerae Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 35
- 206010066476 Haematological malignancy Diseases 0.000 description 2
- 208000009359 Sezary Syndrome Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762567702P | 2017-10-03 | 2017-10-03 | |
| US62/567,702 | 2017-10-03 | ||
| US201862657402P | 2018-04-13 | 2018-04-13 | |
| US62/657,402 | 2018-04-13 | ||
| PCT/US2018/053772 WO2019070591A1 (en) | 2017-10-03 | 2018-10-01 | METHODS OF TREATING BACTERIAL INFECTIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536092A JP2020536092A (ja) | 2020-12-10 |
| JP2020536092A5 true JP2020536092A5 (https=) | 2021-11-11 |
Family
ID=65994826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519066A Pending JP2020536092A (ja) | 2017-10-03 | 2018-10-01 | 細菌感染症の治療方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11376237B2 (https=) |
| EP (1) | EP3691652A4 (https=) |
| JP (1) | JP2020536092A (https=) |
| KR (1) | KR20200066664A (https=) |
| CN (1) | CN111432821A (https=) |
| AU (1) | AU2018345317B2 (https=) |
| BR (1) | BR112020006658A2 (https=) |
| CA (1) | CA3078238A1 (https=) |
| CL (1) | CL2020000892A1 (https=) |
| JO (1) | JOP20200075A1 (https=) |
| MX (1) | MX2020003670A (https=) |
| MY (1) | MY200934A (https=) |
| PH (1) | PH12020550249A1 (https=) |
| SG (1) | SG11202003009QA (https=) |
| TW (2) | TW201922241A (https=) |
| WO (1) | WO2019070591A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11376237B2 (en) | 2017-10-03 | 2022-07-05 | Melinta Subsidiary Corp. | Methods of treating bacterial infections |
| EP4313033A4 (en) * | 2021-03-24 | 2025-04-23 | Trustees Of Tufts College | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912363A (zh) | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
| CA2807546C (en) | 2010-08-10 | 2022-08-23 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| CN102188395B (zh) | 2011-04-29 | 2012-12-05 | 石药集团中诺药业（石家庄）有限公司 | 一种更稳定的美罗培南注射剂及其制备方法 |
| CN102335136B (zh) | 2011-08-02 | 2013-06-12 | 天津市嵩锐医药科技有限公司 | 一种供注射用美罗培南药物组合物及其制备方法 |
| CN102335137B (zh) | 2011-08-02 | 2013-06-12 | 天津市嵩锐医药科技有限公司 | 一种含美罗培南的药物组合物 |
| CN102525961B (zh) | 2012-01-17 | 2013-02-13 | 山东罗欣药业股份有限公司 | 美罗培南组合物注射用粉针剂 |
| US10561675B2 (en) * | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| CN103570718B (zh) | 2012-07-31 | 2016-06-29 | 深圳市海滨制药有限公司 | 一种美罗培南原料药、其制备方法及包含其的药物组合物 |
| RU2675847C2 (ru) | 2013-05-28 | 2018-12-25 | Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми | Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций |
| WO2016172208A1 (en) | 2015-04-24 | 2016-10-27 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| CN108289896B (zh) | 2015-07-09 | 2022-03-01 | 华盛顿大学 | 抗菌药物组合的组合物和使用方法 |
| US9949995B2 (en) | 2015-09-04 | 2018-04-24 | Case Western Reserve University | Compositions and methods of treating of bacterial infections with β-lactamase inhibitors |
| JP7436206B2 (ja) | 2017-01-09 | 2024-02-21 | レンペックス・ファーマシューティカルズ・インコーポレイテッド | 細菌感染症を処置する方法 |
| US11376237B2 (en) * | 2017-10-03 | 2022-07-05 | Melinta Subsidiary Corp. | Methods of treating bacterial infections |
-
2018
- 2018-10-01 US US16/753,288 patent/US11376237B2/en active Active
- 2018-10-01 EP EP18863923.1A patent/EP3691652A4/en active Pending
- 2018-10-01 SG SG11202003009QA patent/SG11202003009QA/en unknown
- 2018-10-01 BR BR112020006658-3A patent/BR112020006658A2/pt not_active Application Discontinuation
- 2018-10-01 WO PCT/US2018/053772 patent/WO2019070591A1/en not_active Ceased
- 2018-10-01 CA CA3078238A patent/CA3078238A1/en active Pending
- 2018-10-01 AU AU2018345317A patent/AU2018345317B2/en not_active Expired - Fee Related
- 2018-10-01 KR KR1020207012784A patent/KR20200066664A/ko not_active Ceased
- 2018-10-01 MX MX2020003670A patent/MX2020003670A/es unknown
- 2018-10-01 JP JP2020519066A patent/JP2020536092A/ja active Pending
- 2018-10-01 MY MYPI2020001141A patent/MY200934A/en unknown
- 2018-10-01 CN CN201880072552.XA patent/CN111432821A/zh active Pending
- 2018-10-01 JO JOP/2020/0075A patent/JOP20200075A1/ar unknown
- 2018-10-02 TW TW107134824A patent/TW201922241A/zh unknown
- 2018-10-02 TW TW112133851A patent/TW202400146A/zh unknown
-
2020
- 2020-04-02 CL CL2020000892A patent/CL2020000892A1/es unknown
- 2020-04-03 PH PH12020550249A patent/PH12020550249A1/en unknown
-
2022
- 2022-05-27 US US17/826,712 patent/US12533342B2/en active Active
-
2025
- 2025-12-16 US US19/421,222 patent/US20260102374A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Trillet-Lenoir et al. | Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy | |
| Steinmetz et al. | Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML | |
| CN110869029A (zh) | 组合癌症治疗 | |
| HK1044466A1 (zh) | 抗腫瘤的協同組合物 | |
| Pein et al. | Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor--a phase II study by the French Society of Pediatric Oncology. | |
| JP2020536092A5 (https=) | ||
| Davila et al. | Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments | |
| JP2021530444A5 (https=) | ||
| Howard et al. | A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia | |
| JP2021516236A5 (https=) | ||
| CN115414351B (zh) | pladienolide B与PD-L1抗体组合在肿瘤免疫治疗领域的应用 | |
| CN115052609A (zh) | 一种治疗癌症的细菌组合物 | |
| US8236811B2 (en) | Therapeutic use for treating of leukemia | |
| CN115779094A (zh) | 癌症联合治疗的组合物与方法 | |
| Scheithauer et al. | Phase II study of amonafide in advanced breast cancer | |
| Saven et al. | 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia | |
| Trof et al. | Spontaneous remission of acute myeloid leukaemia after recovery from sepsis | |
| Beller et al. | Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report | |
| Foon et al. | Acute myelogenous leukemia: current status of therapy in adults | |
| Bessho et al. | Improved prognosis of acute nonlymphocytic leukemia in children: Results of the 12th‐ANLL protocol of Tokyo Children's Cancer Study Group | |
| Pui et al. | Current treatment and results of St. Jude studies for childhood acute lymphoblastic leukemia | |
| Alba et al. | Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs | |
| JPWO2019173229A5 (https=) | ||
| Aravantinos et al. | Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer | |
| TWI912688B (zh) | 用於治療三陰性乳癌之藥物組合物 |